Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with behçet's disease

Ocular Immunology and Inflammation

Volumn 20, Issue 3, 2012, Pages 193-197

  Takeuchi, Masaki ^a   Asukata, Yuri ^a   Kawagoe, Tatsukata ^a   Ito, Norihiko ^a   Nishide, Tadayuki ^a   Mizuki, Nobuhisa ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Beh et's disease; Colchicine; Combination therapy; Infliximab; Monotherapy

Indexed keywords

COLCHICINE; INFLIXIMAB;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MALE; MONOTHERAPY; RETROSPECTIVE STUDY; VISUAL ACUITY;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; COLCHICINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 84860523696     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2012.665124     Document Type: Article

References (27)

1. Cocco G, Chu DC, Pandolf S. Colchicine in clinical medicine: a guide for internists.Eur J Intern Med. 2010;21:503-508.
2. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128-132. (Pubitemid 27059870)
3. Travassos WJ, Cheifetz AS. Infiximab: use in infamma-tory bowel disease. Curr Treat Options Gastroenterol. 2005;8: 187-196. (Pubitemid 40873150)
4. Smolen JS, Emery P. Infiximab: 12 years of experience. Arthritis Res Ther. 2011;25:13 (Suppl 1):S2 Review.
5. Mizushima Y. Recent research into Bechçet's disease in Japan. Int J Tissue React. 1998;10:59-65.
6. Tabbara KF, Al-Hemidan AI. Infiximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet's disease. Am J Ophthalmol. 2008;146:845-50.e1.
7. Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and effcacy of infiximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int. 2008;29:53-57.
8. Accorinti M, Pirraglia MP, Paroli M P, et al. Infiximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol. 2007;51:191-196. (Pubitemid 46889493)
9. Niccoli L, Nannini C, Benucci M, et al. Long-term effcacy of infiximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161-1164. (Pubitemid 47050622)
10. Evereklioglu C. Current concepts in the etiology and treatment of Behçet's disease. Surv Ophthalmol. 2005;50:297-350. (Pubitemid 40828225)
11. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet's disease. Ann Rheum Dis. 2008;67:1656-1662.
12. Brian Feagan, John McDonald, Remo Panaccione, et al. A randomized trial of methotrexate in combination with inf-liximab for the treatment of Crohn's disease. Gastroenterology. 2008;135:294-295.
13. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefts and risks of immunomodulators and maintenance infiximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30:210-226.
14. Colombel JF, Sandborn WJ, Reinisch W, et al. Infiximab, aza-thioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
15. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infiximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
16. Pérez-Guijo VC, Cravo AR, Castro Mdel C, et al. Increased effcacy of infiximab associated with methotrexate in anky-losing spondylitis. Joint Bone Spine. 2007;74:254-258. (Pubitemid 46720042)
17. Iwata S, Saito K, Yamaoka K, et al. Effcacy of combination therapy of anti-TNF-α antibody infiximab and methotrex-ate in refractory entero-Behçet's disease. Mod Rheumatol. 2011;21:184-191.
18. Sfkakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations. Rheumatology (Oxford). 2007;46:736-741. (Pubitemid 47061701)
19. Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61-70.
20. Baert F, Noman M, Vermeire S, et al. Infuence of immuno-genicity on the long-term effcacy of infiximab in Crohn's disease. N Engl J Med. 2003;348:601-608. (Pubitemid 36204954)
21. Maini R, St Clair EW, Breedveld F, et al. Infiximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 1999;354:1932-1939.
22. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic eff-cacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563. (Pubitemid 28459913)
23. Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009;104:2524-2533.
24. Takeuchi T, Miyasaka N, Inoue K, et al. Impact of trough serum level on radiographic and clinical response to infiximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19:478-487.
25. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infiximab and anti-infiximab antibodies. Rheumatology (Oxford). 2007;46:1828-1834. (Pubitemid 350168300)
26. Kopylov U, Mantzaris GJ, Katsanos KH, et al. The effcacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infiximab. Aliment Pharmacol Ther. 2011;33:349-357.
27. Ohno S, Nakamura S, Hori S, et al. Effcacy, safety, and phar-macokinetics of multiple administration of infiximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368. (Pubitemid 38879203)